-

Shareholder Alert: Robbins LLP is Investigating The Chemours Company (CC) on Behalf of Shareholders

SAN DIEGO & WILMINGTON, Del.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that it is investigating the officers and directors of The Chemours Company (NYSE: CC) for breaches of fiduciary duty and violations of the Securities and Exchange Act of 1934. Chemours, a spin-off from DuPont, provides a wide range of industrial and specialty chemicals products for various markets and has a long history of using of perfluoroalkyl and polyfluoroalkyl substances ("PFAS").

If you suffered a loss as a result of Chemours' misconduct, click here.

The Chemours Company (CC) May Have Misled Shareholders

In the 1970s, DuPont's company scientists became aware that PFAS posed negative health risks, including liver damage and birth defects. To address the mounting liability of PFAS, which were becoming the basis for environmental regulatory actions and governmental prosecutions, in 2015 DuPont spun off Chemours to shift the responsibility of its environmental liabilities onto Chemours. Chemours concealed these facts and assured investors that liabilities were "well understood [and] well managed" and that it was accurately reserving for its potential liabilities. On May 6, 2019, Glenview Capital Management revealed that Chemours' environmental liabilities and true PFAS exposure was between $4 - $6 billion, dramatically higher than Chemours' average liability accruals. Then, Chemours' complaint against DuPont – in which Chemours seeks a ruling that its environmental exposures were so large and its reserves so deficient that it was actually insolvent at the time of spin-off – was unsealed revealing that contrary to its public statements concerning the adequacy of its reserves, Chemours had insufficient financial resources to pay for its environmental liabilities. Finally, on August 1, 2019, Chemours lowered its full-year guidance, reducing its cash flow outlook from over $550 million to just $100 million. Following these disclosures, Chemours' stock price plummeted 57% and has yet to recover.

The Chemours Company (CC) Shareholders Have Legal Options

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against The Chemours Company settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003 or (619) 525-3990
www.robbinsllp.com

Robbins LLP

NYSE:CC

Release Versions
$Cashtags

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003 or (619) 525-3990
www.robbinsllp.com

More News From Robbins LLP

Stockholder Alert: Robbins LLP Informs Investors of the Flotek Industries, Inc. (FTK) Class Action

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Flotek Industries, Inc. (NYSE: FTK) securities between August 3, 2026 and August 17, 2026 (the "Class Period"). Flotek is an energy technology and services company.The complaint alleges that Flotek misled investors by failing to disclose the cancellation of its $400m Puerto Rican deal.Investors who suffered s...

Robbins LLP Encourages WSE Stockholders with Large Losses to Seek Counsel for the Securities Class Action Lawsuit Against Wise Group plc

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Wise Group plc (NASDAQ: WSE) securities between May 11, 2026 and July 23, 2026 (the "Class Period").The complaint alleges that Wise and certain of its senior executives violated the federal securities laws by making materially false and/or misleading statements regarding the Company's anti-money laundering compliance, a...

Robbins LLP Urges Investors of ARS Pharmaceuticals Inc. to Contact the Firm for Information About the SPRY Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds shareholders that a securities class action has been filed on behalf of all investors who purchased or otherwise acquired ARS Pharmaceuticals Inc. (NASDAQ: SPRY) securities between March 9, 2026 and June 24, 2026 (the "Class Period"). ARS is a clinical stage biopharmaceutical company focused on the development and commercialization of neffy for needle-free intranasal delivery of epinephrine for emergency treatment of Type 1 allergic reactions, incl...
Back to Newsroom